Core Viewpoint - Kanglong Chemical experienced a decline of 5.02% on November 17, with a stock price of 29.90 yuan per share and a total market capitalization of 53.168 billion yuan [1] Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, and went public on January 28, 2019. The company is located in Beijing Economic and Technological Development Zone [1] - The main business segments include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and large molecule and cell & gene therapy services (3.28%) [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Kanglong Chemical, with the Xinda Health China Mixed A Fund (003291) holding 959,400 shares, representing 5.41% of the fund's net value, making it the third-largest holding [2] - The fund has experienced a floating loss of approximately 1.5159 million yuan as of the latest data [2] Fund Manager Performance - The fund manager Li Junzhou has been in position for 165 days, with a total fund size of 634 million yuan and a best return of 11.17% during his tenure [3] - Yang Ke, another fund manager, has been in position for 5 years and 190 days, managing a total fund size of 1.324 billion yuan, with a best return of 43.77% during his tenure [3]

格隆汇11月17日丨根据联交所最新权益披露资料显示，2025年11月12日，康龙化成(03759.HK)获Norges Bank在场内以每股均价23.8072港元增持70.02万股，涉资约1667万港元。 | 芸植序线 | 大股東/董事/最高行政人員名 作出技擺的 買入 / 变出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的海關事件的日 相關法國股 債權證權益 | | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | ( 調金関上述*註 有投票權股期(日/月/ 份權益 | | | | | | | 份百分比 年) | | | | | | | ( 96 ) 日 1985 | | CS20251113E00453 Norges Bank | 700.200(L) | 1101(L) | | HKD 23.8072 | 18,270,424(L) 6.21(L)12/11/2025 | 增持后，Norges Bank最新持股数目为18,270,424股，持股比例由5.97%上升至6.21%。 ...

Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership dynamics and investor sentiment in the market [1]. Shareholder Reductions - Guosheng Securities: Three shareholders plan to collectively reduce their holdings by no more than 2.82% [1] - Binjiang Group: Multiple shareholders intend to reduce their stakes by up to 2.88% [1] - Kanglong Chemical: Shareholder Xincheng Kang and its concerted parties plan to reduce their holdings by no more than 1.5% [1] - Erliang San: Controlling shareholder Li Xiaolong intends to reduce his stake by no more than 1% [1] - Yongxing Shares: Science City Investment Group plans to reduce its holdings by no more than 1% [1] - Weike Technology: Industrial Investment intends to reduce its stake by no more than 0.9999% [1] - Zhengyuan Wisdom: Plans to reduce no more than 2% of repurchased shares [1] - Baida Group: Shareholder Xizi United plans to reduce up to 752.48 million shares [1] - Camel Shares: Chairman Liu Changle intends to reduce no more than 7.2 million shares [1] - Zhongwei Company: Xunxin Investment has cumulatively reduced 12.52 million shares through block trading [1] - Aerospace Engineering: Guochuang Fund and New Car Fund have collectively reduced 2.76 million shares [1] - Tengya Precision: Nanjing Yunhang has cumulatively reduced 2.49% of its shares [1] - Hexing Packaging: Xia Ping and its concerted parties have cumulatively reduced 3.4045% of their shares [1] Other Notable Information - *ST Dazheng: Shareholder Zhou Zhenke's 0.81% stake is set to be forcibly sold by judicial order [1] - Dongbai Group: Lacks duty-free operating qualifications and is not involved in duty-free goods operations [1]

Core Viewpoint - The company 康龙化成 (300759.SZ) has received a share reduction plan notification from its major shareholders, indicating potential changes in ownership structure and market sentiment [1] Shareholder Reduction Plans - Shareholder 信中康成 holds 223,488,310 shares, approximately 12.57% of the total share capital, and plans to reduce its holdings by up to 8,890,977 shares, which is 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - Shareholder 信中龙成 holds 28,498,500 shares, about 1.60% of the total share capital, and intends to reduce its holdings by up to 17,781,955 shares, representing 1% of the total share capital, within the same three-month period [1]

Core Viewpoint - The company 康龙化成 (300759.SZ) has announced that its major shareholders, 深圳市信中康成投资合伙企业 and 深圳市信中龙成投资合伙企业, plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - 深圳市信中康成 plans to reduce its holdings by up to 8.891 million shares, which represents 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - 深圳市信中龙成 plans to reduce its holdings by up to 17.782 million shares, which represents 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - Kanglong Chemical (300759.SZ) announced that major shareholders plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - Shenzhen Xinchongkangcheng Investment Partnership (Limited Partnership) plans to reduce its holdings by up to 8.891 million shares, representing 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xinchonglongcheng Investment Partnership (Limited Partnership) intends to reduce its holdings by up to 17.782 million shares, accounting for 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - Kanglong Chemical (SZ 300759) announced a share reduction plan from major shareholders, which may impact the stock's performance and investor sentiment [1] Shareholder Reduction Plan - Shenzhen Xinchongkang Investment Partnership plans to reduce its holdings by up to approximately 8.89 million shares, accounting for 0.5% of the total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xinchonglong Investment Partnership plans to reduce its holdings by up to approximately 17.78 million shares, accounting for 1% of the total share capital, within the same timeframe [1] Financial Performance - For the year 2024, Kanglong Chemical's revenue composition is as follows: 99.95% from scientific research and technical services, and 0.05% from other businesses [1] - As of the report date, Kanglong Chemical's market capitalization stands at 56 billion yuan [1]

Core Viewpoint - The company announced that major shareholders plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - Shenzhen Xinchongkangcheng Investment Partnership (Limited Partnership) holds 223,488,310 shares, approximately 12.57% of the total share capital, and plans to reduce up to 8,890,977 shares, which is 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xindlongcheng Investment Partnership (Limited Partnership) holds 28,498,500 shares, approximately 1.60% of the total share capital, and plans to reduce up to 17,781,955 shares, which is 1% of the total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - 康龙化成 announced a share reduction plan by major shareholders, which may impact the stock's market performance and investor sentiment [1] Shareholder Reduction Plans - 深圳市信中康成投资合伙企业 plans to reduce its holdings by up to 8,890,977 shares, representing approximately 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - 深圳市信中龙成投资合伙企业 intends to reduce its holdings by up to 17,781,955 shares, accounting for about 1% of the total share capital, also within three months starting from December 8, 2025 [1] - 信中康成 currently holds 223,488,310 shares, which is about 12.57% of the total share capital, while 信中龙成 holds 28,498,500 shares, approximately 1.60% of the total share capital [1]

Pharmaron Beijing Co., Ltd. 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年11月14日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-064 康龙化成（北京）新药技术股份有限公司 ...